The Lancet. Oncology
Authors: Cuzick J, Chu K, Keevil B, Brentnall AR, Howell A, Zdenkowski N, Bonanni B, Loibl S, Holli K, Evans DG, Cummings S, Dowsett M
BMJ (Clinical research ed.)
Authors: Chen TK, Hoenig MP, Nitsch D, Grams ME
PloS one
Authors: Goldman ML, McDaniel M, Manjanatha D, Rose ML, Santos GM, Shade SB, Lazar AA, Myers JJ, Handley MA, Coffin PO
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Authors: Chamie G, Luetkemeyer AF
Best practice & research. Clinical rheumatology
Authors: Parodis I, Lanata C, Nikolopoulos D, Blazer A, Yazdany J
Transplantation
Authors: Zhou K, Lit A, Kuo LS, Thompson LK, Dodge JL, Mehta N, Terrault NA, Ha NB, Cockburn MG
LGBT health
Authors: Mayer KH, Peretti M, McBurnie MA, King D, Smith NX, Crawford P, Loo S, Sigal M, Gillespie S, Davis JA, Cahill S, Grasso C, Keuroghlian AS
Annals of surgery
Authors: Keny C, Dillon EC, Russell MM, Colley A, Yank V, Tang V
ESC heart failure
Authors: Soussi S, Ahmadiankalati M, Jentzer JC, Marshall JC, Lawler PR, Herridge M, Mebazaa A, Gayat E, Lu Z, Dos Santos CC, French and European Outcome Registry in Intensive Care Units (FROG-ICU) and CCCTBG trans-trial group
Volume 2 of Issue 6Part B | Journal of the Society for Cardiovascular Angiography & Interventions
Authors: Seligman H, Vora AN, Haroian NQ, Puri R, Heng EL, Smith RD, Latib A, Makkar R, Sorajja P, Leon MB, Ahmad Y
Tricuspid regurgitation (TR) is common, and its prevalence increases with age. It was previously estimated that there are 1.6 million patients in the United States with moderate or worse TR, and more contemporary data suggest the age-adjusted prevalence of TR is 0.55%. Increasing TR severity is associated with an adverse prognosis independent of the pulmonary artery pressure and the degree of right heart failure. In heart failure with reduced ejection fraction, survival is significantly worsened when moderate or severe TR is present. The mainstay of therapy has traditionally been surgery, but outcomes are poor. There has been increasing attention on the potential role of transcatheter interventions for TR. Numerous platforms are in developmental evolution, which broadly fall into 3 categories: valve replacement, valve repair (subdivided into annular, leaflet, and chordal platforms), and caval valve implantation. In this review, we examine all these strategies and devices, including guidance on how to appropriately select patients who can benefit from intervention.
View on PubMed
